Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P. Arylaminomethylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorganic & medicinal chemistry. 2013; 21(21): 6456-65.
Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P. Arylaminobisphosphonates: potent and selective inhibitors of the tumor-associated carbonic anhydrase XII. Bioorganic & medicinal chemistry letters. 2014;24(8): 1941-3.
Tauro M, Loiodice F, Ceruso M, Supuran CT, Tortorella P. Dual carbonicanhydrase/matrix metalloproteinase inhibitors incorporating bisphosphonic acidmoieties targeting bone tumors. Bioorg Med Chem Lett. 2014; 24(12): 2617-20.
Tauro M, McGuire J, Lynch CC. New approaches to selectively target cancer associated matrix metalloproteinase activity. Cancer & MetastasisReviews Cancer Metastasis Rev., 2014 Oct 18.
Campestre C, Agamennone M, Tauro M, Tortorella P, Phosphonate Emerging Zinc Binding Group inMatrix Metalloproteinase Inhibitors. Current Drug Targets, in press.
Piemontese L, Fracchiolla G, Carrieri A, Parente M, Laghezza A, Carbonara G, Sblano S, Tauro M, Gilardi F, Tortorella P, Lavecchia A, Crestani M, Desvergne B, Loiodice F; Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175; Eur J Med Chem. 2014 Nov 24;90C:583-594.